EP4701639A1 - Molécules ciblant des tissus infectés et leurs procédés d'utilisation - Google Patents

Molécules ciblant des tissus infectés et leurs procédés d'utilisation

Info

Publication number
EP4701639A1
EP4701639A1 EP24735441.8A EP24735441A EP4701639A1 EP 4701639 A1 EP4701639 A1 EP 4701639A1 EP 24735441 A EP24735441 A EP 24735441A EP 4701639 A1 EP4701639 A1 EP 4701639A1
Authority
EP
European Patent Office
Prior art keywords
seq
forms
peptide
infected tissue
residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24735441.8A
Other languages
German (de)
English (en)
Inventor
Tambet Teesalu
Erkki Ruoslahti
Gregory T. Robertson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tartu Ulikool (University of Tartu)
Colorado State University Research Foundation
Original Assignee
Tartu Ulikool (University of Tartu)
Colorado State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tartu Ulikool (University of Tartu), Colorado State University Research Foundation filed Critical Tartu Ulikool (University of Tartu)
Publication of EP4701639A1 publication Critical patent/EP4701639A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Des polypeptides qui ciblent sélectivement un tissu infecté et/ou des pathogènes microbiens in vivo et qui s'y lient ont été découverts. Des agents antimicrobiens et des agents de diagnostic tels que des colorants qui sont conjugués aux molécules de localisation de tissu infecté sont efficacement ciblés sélectivement sur des tissus infectés et/ou des pathogènes microbiens in vivo. L'invention concerne des compositions et des procédés de molécules de liaison de tissu infecté pour la localisation sélective de tissus infectés. Dans certains modes de réalisation, les compositions comprennent des nanoparticules, telles que des nanoparticules d'argent, conjuguées aux peptides de localisation de tissu infecté et chargées d'agents antimicrobiens. Généralement, la quantité d'antimicrobien qui est nécessaire pour traiter ou prévenir une infection par des pathogènes tels que Mycobacterium tuberculosis (Mtb) lorsqu'elle est administrée dans les nanoparticules est inférieure à la quantité du même antimicrobien administré seul.
EP24735441.8A 2023-05-31 2024-05-30 Molécules ciblant des tissus infectés et leurs procédés d'utilisation Pending EP4701639A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363470002P 2023-05-31 2023-05-31
PCT/US2024/031548 WO2024249553A1 (fr) 2023-05-31 2024-05-30 Molécules ciblant des tissus infectés et leurs procédés d'utilisation

Publications (1)

Publication Number Publication Date
EP4701639A1 true EP4701639A1 (fr) 2026-03-04

Family

ID=91620594

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24735441.8A Pending EP4701639A1 (fr) 2023-05-31 2024-05-30 Molécules ciblant des tissus infectés et leurs procédés d'utilisation

Country Status (2)

Country Link
EP (1) EP4701639A1 (fr)
WO (1) WO2024249553A1 (fr)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US6509323B1 (en) 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
EP1817003B1 (fr) 2004-10-29 2018-02-21 The Regents of The University of California Microparticules de silicium poreux pour l'administration oculaire de medicaments
CN101815504B (zh) 2007-07-10 2013-11-20 加利福尼亚大学董事会 用于向所选择组织递送组合物的材料和方法
US8404636B2 (en) * 2008-07-17 2013-03-26 George Mason Intellectual Properties, Inc. Targeted delivery of antimicrobial agents
WO2016172515A1 (fr) * 2015-04-23 2016-10-27 Sanford Burnham Prebys Medical Discovery Institute Système d'administration ciblée et procédés d'utilisation correspondants
CN114533898B (zh) 2015-07-09 2025-07-01 加利福尼亚大学董事会 融合脂质体包被的多孔硅纳米颗粒
WO2018085846A1 (fr) * 2016-11-07 2018-05-11 The Regents Of The University Of California Conjugués antibiotiques-peptides multifonctionnels : synthèse et activités antimicrobiennes
US20210000744A1 (en) 2018-03-27 2021-01-07 The Regents Of The University Of California Drug delivery formulations
WO2020161602A1 (fr) * 2019-02-04 2020-08-13 University Of Tartu Peptides de liaison à la matrice extracellulaire bi-spécifiques et procédés d'utilisation de ceux-ci

Also Published As

Publication number Publication date
WO2024249553A1 (fr) 2024-12-05

Similar Documents

Publication Publication Date Title
US20240042063A1 (en) LINKED AND OTHER pH-TRIGGERED COMPOUNDS
US20210052507A1 (en) Drugs and gene carrier particles that rapidly move through mucous barriers
CA2722183C (fr) Nanostructures appropriees pour la sequestration du cholesterol et d'autres molecules
US11554097B2 (en) Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
JP2008540544A (ja) Ｒｎａｉｉｉ阻害ペプチドを投与するための組成物
JP2017502931A5 (fr)
Papadia et al. Multifunctional LUV liposomes decorated for BBB and amyloid targeting. A. In vitro proof-of-concept
BR112016030172B1 (pt) Aptâmeros específicos para tlr-4 e usos dos mesmos
WO2012112767A2 (fr) Nanoparticules ciblées sur le collagène
AU2020218940B2 (en) Bi-specific extracellular matrix binding peptides and methods of use thereof
US11952431B2 (en) Neutrophil-binding peptides
ES2872552T3 (es) Nanopartículas poliméricas y métodos de preparación y de uso de las mismas
EP4701639A1 (fr) Molécules ciblant des tissus infectés et leurs procédés d'utilisation
WO2014059385A1 (fr) Procédés et thérapie à base de petites molécules comportant un elps fondu
WO2017210693A1 (fr) Fusions de polymères protéiques pour l'administration sous-cutanée de petites molécules
JP2022501423A (ja) 医薬ベシクル製剤を調製するための方法、ならびに関連する製品および使用
WO2012118778A1 (fr) Peptides car tronqués, procédés et compositions les utilisant
US20200268832A1 (en) Compositions for delivery to and treatment of atherosclerotic plaques
JP5250229B2 (ja) カーボンナノホーン
JP2018534317A (ja) 結腸がんの処置および検出のための組成物および方法
Rani et al. Engineered Bacterial Membrane Vesicles for Advanced Biomedical Applications
Pérez-Guillén et al. Studying Lipid Membrane Interactions of a Super-Cationic Peptide in Model Membranes and Living Bacteria. Pharmaceutics 2022, 14, 2191
HK40090445A (zh) 靶组织特异性递送型药物递送系统用胶囊的用途
WO2021155198A1 (fr) Nanomatériaux pour le traitement ciblé et l'imagerie de microenvironnement anévrismal

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251124

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR